How Soon Is Now:
Shaping the Future of Gynecologic Oncology - Second Edition

INOC - Istituto Nazionale Oncologico Candiolo
December 11-12, 2026

Congress President
Luigi Carlo Turco (Candiolo, TO)

Scientific Director
Luigi Carlo Turco (Candiolo, TO)

Scientific Secretariat
Benedetta Alberghetti (Candiolo, TO)
Alice Zampolini Faustini (Candiolo, TO)
Antonella Biscione (Candiolo, TO)
Felice Borghi
Riccardo Ponzone
Maristella Bungaro (Candiolo, TO)
Michela Zorzi (Candiolo, TO)

SCIENTIFIC RATIONALE

Gynecologic oncology is undergoing a period of profound evolution, driven by the integration of surgical innovation, molecular characterization, and the development of new therapeutic strategies. In this rapidly changing landscape, continuous scientific education is essential to ensure increasingly effective and personalized care pathways for patients.

The “How Soon Is Now 2026” congress was conceived to discuss the major changes that are redefining the management of gynecologic malignancies. With the participation of national and international opinion leaders, the meeting will provide a unique opportunity to discuss the latest scientific evidence and future perspectives in the field.

Particular attention will be devoted to ovarian cancer, in light of the new international guidelines presented in 2026, which have further refined diagnostic and therapeutic algorithms, patient selection, and the integration of different treatment options across the various phases of disease.

In endometrial cancer, the growing role of molecular pathology is profoundly changing clinical management. Molecular classification now represents a key tool for prognostic stratification and treatment personalization, enabling increasingly precise and biologically driven patient management.

Considerable attention will also be given to the new opportunities offered by innovative and biologic treatments, including immunotherapy, antibody-drug conjugates, and other targeted therapies, which are significantly expanding treatment options in gynecologic malignancies.

A dedicated session will focus on rare gynecologic tumors, an area characterized by major unmet clinical and scientific needs, in which collaboration among referral centers and the sharing of expertise are essential to improve the quality of care.

The aim of the meeting is to foster discussion among national and international experts on the most innovative topics in gynecologic oncology, promoting a multidisciplinary approach focused on innovation, personalized care, and improved patient outcomes.

TARGET AUDIENCE

- Physicians: General Surgeons, Medical Oncologists, Gynecologists, Pathologists, Clinical Biochemists, Radiologists
- Biologists
- Nurses
- Psychologists

Expected participants: 150
Accreditation: CME-accredited event

CONGRESS PROGRAM
FRIDAY, DECEMBER 11, 2026

08:30 - 09:00: Registration

09:00 - 09:10: Welcome and opening remarks

Scientific Director: Luigi Carlo Turco

Honorary Presidents: Chiara Benedetto; Paolo Scollo; Elsa Viora

SESSION I - Endometrial Cancer

09:15 - 09:30: State of the art: ESGO guidelines on endometrial cancer and FIGO staging in the era of molecular classification and tumor biology.

- **Christian Marth**

09:30 - 09:45: Contemporary surgical strategies in endometrial cancer: staging, radicality, and innovation.

- **Ignacio Zapardiel**

09:45 - 10:00: Robotic surgery in endometrial cancer: current standards and future perspectives.

- **Enrico Vizza**

10:00 - 10:30: Coffee break

10:30 - 10:45: How molecular pathology is redefining the management of endometrial cancer.

- **Camilla Nero**

10:45 - 11:00: Systemic treatment of advanced and recurrent endometrial cancer: toward personalized therapy.

- **Giorgio Valabrega**

11:00 - 11:15: Fertility-sparing treatment in endometrial cancer: indications, limits, and follow-up.

- **Ursula Catena**

11:15 - 12:00: Discussion

12:00 - 12:30: Round table and contributions from patient associations

The Voice of Patients: associations, care, and the future of gynecologic cancer
Mind Your Cancer - ETS ACTO ALTO ABRACADABRA

12:30 - 13:30: Lunch

SESSION II - Rare Gynecologic Tumors and Special Situations

From rarity to expertise

13:30 - 13:45: Gynecologic cancers in pregnancy: balancing maternal and fetal outcomes.

- **Frederic Amant**

13:45 - 14:00: Immunotherapy-related pseudoprogression: radiological challenges and clinical implications.

- **Evis Sala**

14:00 - 14:15: Hot topics in rare gynecologic malignancies.

- **Alice Bergamini**

14:15 - 14:30: Integrative diagnosis in rare gynecologic tumors: morphology, molecular features, and networks.

- **Caterina Marchiò**

14:30 - 15:00: Coffee break

15:00 - 15:15: Sexuality after cancer and iatrogenic menopause (desire, GSM, metabolic syndrome).

- **Alessandra Graziottin**

15:15 - 15:30: Risk-reducing surgery in hereditary gynecologic cancers: ovary, endometrium, and beyond.

- **Robert Fruscio**

15:30 - 16:00: Discussion

WORKSHOPS

16:00 - 17:00

• Workshop 1: Ultrasound in gynecologic oncology: from diagnosis to surgical planning

New IOTA terminology, IETA assessment of the endometrium, adnexal masses, and preoperative triage.

Faculty: Antonella Biscione; Francesca Ciccarone; Ilaria De Blasis; Michela Zorzi
Format: Image-based interactive session

• Workshop 2: Advanced Gynecologic Oncology: Surgical Anatomy and Management of Complications

Pelvic spaces, upper abdominal anatomy, and surgical decision-making.

Faculty: Stefano Cosma; Denis Querleu; Andrea Rosati; Vito Chiantera; Giuseppe Vizzielli
Format: Video-based interactive session

SATURDAY, DECEMBER 12, 2026

08:30 - 09:00: Registration

SESSION III - Ovarian Cancer

09:00 - 09:15: Ovarian cancer after TRUST and new international guidelines: what is changing in surgical strategy?

- **Anna Fagotti**

09:15 - 09:30: HIPEC in advanced ovarian cancer: evidence, patient selection, and open questions.

- **Pierandrea De Iaco**

09:30 - 09:45: Limitations of PDS/IDS/SCS: elderly patients and perioperative complications.

- **Francesco Fanfani**

09:45 - 10:15: Discussion

10:15 - 10:45: Coffee break

10:45 - 11:00: Metastatic and oligometastatic recurrent ovarian cancer: surgery, radiotherapy, or systemic treatment?

- **Fabio Martinelli**

11:00 - 11:15: Current and future systemic treatment landscape in ovarian cancer: immunotherapy, ADCs, and beyond.

- **Domenica Lorusso**

11:15 - 11:30: Maintenance therapy in ovarian cancer: the right treatment for the right patient.

- **Claudia Machetti**

11:30 - 11:45: Reshaping the definition of platinum resistance and new frontiers: current challenges and emerging therapeutic options.

- **Sabrina Cecere**

11:45 - 12:00: Old and new toxicities in the era of modern cancer treatment.

- **Vanda Salutari**

12:00 - 12:30: Discussion

12:30 - 13:00: Final assessment